<DOC>
	<DOCNO>NCT02728206</DOCNO>
	<brief_summary>This study evaluate antiviral efficacy , safety , tolerability sofosbuvir/velpatasvir ( SOF/VEL ) fixed-dose combination ( FDC ) hepatitis C virus ( HCV ) -infected adult undergo liver transplantation .</brief_summary>
	<brief_title>Sofosbuvir/Velpatasvir Fixed-Dose Combination HCV-Infected Adults Who Are Undergoing Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key HCVinfected , male nonpregnant/nonlactating female , undergo liver transplantation Key Receiving HCVinfected liver HIV hepatitis B virus ( HBV ) coinfected Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>